Meningitis B vaccine Bexsero is released in Korea

By Moon, sung-ho | translator Kang, Shin-Kook

24.07.25 05:45:52

가나다라 0

GSK Korea launches the drug 2 years after its approval in Korea…will establish a line-up with its other vaccine, Menveo

Non-reimbursement inoculation price will be in the KRW 150,000 range…its effect in preventing meningococcal group B disease gains attention

Competition in the 'meningococcal' vaccine market, which is mainly vaccinated in pediatric clinics, has recently been reignited.

Although its domestic market is worth less than KRW 10 billion, the emergence of next-generation vaccines is expected to spark new competition among multinational pharmaceutical companies.

#This is because GSK, the market leader, has launched Bexsero (meningococcal serogroup B vaccine), a next-generation vaccine.

Professor Hyunmi Kang (Department of Pediatrics, St. Mary's Hospital, Seoul) explained the clinical implications of the introduction of Bexsero at an event held by GSK on the 16th.

Meningococcal meningitis is a statutory C

Moon, sung-ho(lib6983@dailypharm.com)

If you want to see the full article, please JOIN US (click)